ACtive Catheterization for EndovaScular TreatmentS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-27

Study Completion Date

2022-08-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this clinical investigation is to evaluate the safety and technical success of the Basecamp Vascular controllable directional GECKO guidewire when used to facilitate endovascular access to the targeted vessel in order to treat the vascular lesion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NEUROvascular NAVigation With Remotely Controlled Deflectable Guidewire, Study I (NeuroNAV Study I)

NCT06972953

Unruptured Cerebral Aneurysm

RECRUITING NA

Goal-directed Therapy in Endovascular Coiling of Cerebral Aneurysm Patients

NCT02507999

Cerebral Aneurysm

COMPLETED NA

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

NCT00826059

Ischemic Stroke

COMPLETED NA

Safety and Efficacy of Neuroform3TM for Intracranial Aneurysm Treatment

NCT00928265

Intracranial Aneurysm

COMPLETED

Intravenous Stem Cells After Ischemic Stroke

NCT00875654

Ischemia Stroke

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Basecamp Vascular trial is a prospective monocenter, non-randomized, open clinical investigation of their controllable directional GECKO guidewire which has not yet received the CE mark. The GECKO active guidewire is a sterile, single-use device to be used by interventional neuroradiologists (INR) to position a distal access catheter (DAC). The device is a system composed of a deflector (the guide) and a handle. The handle contains the battery and integrated electronics. The device can be activated using buttons on the handle. When the user presses a button, a current is transmitted along the guide to its end: this allows the guide to bend (two possible curves). The end of the device can then take an "S" shape. In INR, the placement of a DAC (at the cervical level) is the first step of an endovascular intervention (Primary Access). This is followed by the treatment phase of the vascular pathology with other medical devices (example: embolization, angioplasty). The GECKO active guide is a system that facilitates endovascular navigation and allows the positioning of the DAC via vascular access (femoral or radial artery). The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unruptured Intracranial Aneurysm Arteriovenous Cerebral Malformations Carotid Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is a prospective monocenter, non-randomized, open clinical investigation to evaluate the safety and technical success of the Basecamp Vascular controllable directional GECKO guidewire when used to facilitate endovascular access to the targeted vessel in order to treat the vascular lesion.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GECKO Active Guidewire Use

All patients will be treated using the GECKO guidewire to facilitate endovascular access to the targeted vessel in order to treat the vascular lesion.

Group Type EXPERIMENTAL

GECKO Active Guidewire

Intervention Type DEVICE

The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GECKO Active Guidewire

The GECKO device is intended to introduce devices used for treatment, at a desired anatomical location (cervical carotid artery, for example) in the central circulatory system. The GECKO guidewire itself is not meant to perform a treatment but is used to set the primary access that will allow performance of the treatments.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female ≥18 years old.
2. An unruptured intracranial aneurysm, a brain arteriovenous malformation (bAVM) or dural arteriovenous fistula (DAVF) or an internal carotid artery (ICA) stenosis.
3. Subject can receive, if necessary, anti-coagulation and anti-platelet therapy according to the standard used in each study center.
4. Subject is eligible to undergo a procedure with the use of contrast media.
5. Subject is willing to comply with protocol requirements and return to the treatment center for all required clinical evaluations and follow-up.
6. Subject has given written informed consent.
7. Life expectancy \>12 months.

Exclusion Criteria

1. Subject is unconscious and unable to directly provide his/her written informed consent.
2. Subject with a type 3 aortic arch will be excluded from the study.
3. Subject is or has been treated with radiation therapy to the neck or chest.
4. Subject has a life-threatening allergy to contrast media (unless treatment for allergy can be tolerated).
5. Subject has a known cardiac disorder, likely to be associated with cardio-embolic symptoms such as atrial fibrillation (AFib).
6. Subject has any condition, which in the opinion of the treating physician, would place the subject at a high risk of embolic stroke.
7. Subject is unable to complete the required follow-up.
8. Subject is pregnant or breastfeeding. (Females of childbearing potential who are less than 45 years old must have a pregnancy test and provide written proof that they are not pregnant prior to inclusion.)
9. Subject has participated in a clinical study within the last 30 days.
10. Subject with cardiac pacemaker or defibrillator.
11. Persons under guardianship or curatorship.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No